Data show none of the treated volunteers to develop COVID-19 experienced a severe form of the disease, versus 11 given placebo.
Moderna’s coronavirus 2019 (COVID-19) vaccine candidate mRNA-1273 is associated with 94.5% efficacy in preventing the virus, according to preliminary results from its ongoing phase 3 trial.
In a report from the New York Times this morning, the biotechnology company’s recently-submitted data to an independent data safety monitoring board reported that of the 95 participants in its phase 3 COVE trial to contract COVID-19, just 5 were vaccinated with the two-dose candidate, and 90 had received placebo.
None of the infected patients to receive mRNA-1273 developed severe COVID-19, while 11 (12%) of the placebo arm did.
The company now wants to submit the candidate to the US Food and Drug Administration (FDA) for emergency use authorization (EUA) following the review of its currently available safety data.
The news of Moderna’s preliminary, non-published phase 3 results come exactly 1 week following an announcement from Pfizer that its vaccine candidate BNT162, in collaboration with BioNTech, achieved 90% efficacy in COVID-19 prevention in its earliest preliminary data from its phase 3 trial.
Moderna Chief Executive Officer Stéphane Bancel, said in a statement that this is the first “clinical validation that our vaccine can prevent COVID-19 disease, including severe disease.”
The phase 3 COVE trial, designed in collaboration with the FDA and NIAID parent organization the National Institutes of Health (NIH), included US persons at greatest risk of COVID-19 severity—including 7000-plus volunteers aged ≥65 years old and 5000-plus with high-risk chronic conditions.
According to Moderna, these high-risk groups represent 42% of the total study participants.
This story first appeared in ContagionLive!®
Healing With Algorithms: AI's Impact on Epidemiology and Infection Control
April 2nd 2024Media in the US presents AI as both beneficial and risky. Positive coverage shows AI's potential through virtual assistants like Siri, while cautionary tales warn of misuse like misinformation and deepfakes. How does all this work in health care?
Four Years After COVID-19: What Has the Infection Prevention Community Learned?
March 15th 2024Four years ago today, March 15, 2020, the COVID-19 lockdown began, and since then, the world has undergone significant changes. It has been a terrifying experience for everyone, especially for the infection prevention community, both within and outside of the health care sector. However, a crucial question remains unanswered: What has the infection prevention community learned from this pandemic, and where does it go from here?
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.